Latest filing published 15 Oct 2019 for Anterix Inc., €4.2M.
Based on 39 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by Stephen Feinberg span 14 companies, the busiest being Anterix Inc., Orbimage Inc and Molecular Insight Pharmaceuticals, Inc. In total, 119 filings cover trades dated from 3 May 2006 to 11 October 2019.
In open-market terms, that means 81 purchases worth €165.8M on one side and 30 sales worth €837.1M on the other. Taken together, the sales exceed the purchases by €671.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2019 alone, the filings show no purchases and 14 sales.
The median purchase comes to €770k. Ninety days after publication, 39 purchases show a median change of -18.9%, with the price up in 5% of them. Past outcomes like these are no guarantee of what comes next.
Most recently, on 15 October 2019, the filings show an open-market sale worth €4.2M in Anterix Inc. The last insider purchase was made public on 15 October 2015, 4,026 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 119 declarations